NSE: ASTEC | BSE: 533138

Weak Stock

Download real time

660.05 -1.40 (-0.21%)

Near 52W Low of ₹629.78

26,365 NSE+BSE Volume

NSE 31 Oct, 2025 3:31 PM (IST)

1,470.7

Market Cap

Above industry Median

0.6

Beta 1Year

Very Low volatility

Rapid Results

Q2FY26 Quarterly Result Announced for Astec Lifesciences Ltd. See details

Astec Lifesciences Ltd. share price target and research reports

Name: Latest research reports of Astec Lifesciences Ltd. authored by ICICI Direct and published by - Trendlyne research reports.
Item: Astec Lifesciences Ltd.
Rating: 1
Author: ICICI Direct

Latest analyst research reports with target prices and PDF download for ASTEC, BSE:533138 Astec Lifesciences Ltd.

Search Inside the pdf :

Astec Lifesciences Ltd.

18 May 2023

660.05

-0.21%

Astec Lifesciences

Sell: Astec Lifesciences Ltd.

Target

ICICI Direct

Astec Lifesciences Ltd. has lost -27.17% in the last 3 Months

Astec Lifesciences Ltd.

09 Feb 2023

660.05

-0.21%

Astec Lifesciences

Sell: Astec Lifesciences Ltd.

Recommendation Target

ICICI Direct

Astec Lifesciences Ltd. has lost -17.98% in the last 1 Month

Astec Lifesciences Ltd.

27 Jul 2022

660.05

-0.21%

Astec Lifesciences

Buy: Astec Lifesciences Ltd.

ICICI Direct

Astec Lifesciences Ltd. has lost -17.98% in the last 1 Month

Astec Lifesciences Ltd.

04 May 2022

660.05

-0.21%

Astec Lifesciences

Buy: Astec Lifesciences Ltd.

ICICI Direct

Astec Lifesciences Ltd. has lost -38.80% in the last 1 Year

Astec Lifesciences Ltd.

28 Oct 2021

660.05

-0.21%

Astec Lifesciences

Buy: Astec Lifesciences Ltd.

ICICI Securities Limited

Astec Lifesciences Ltd. is trading below all available SMAs

Astec Lifesciences Ltd.

07 May 2019

660.05

-0.21%

Price hikes to support margin expansion in animal feed

Buy: Astec Lifesciences Ltd.

Motilal Oswal

Revenue grew 12.5% YoY to segment (+22% YoY to INR8.3b). EBITDA margin shrank 60bp YoY to 5.6% 7 May 2019 lower employee cost and other expenses. EBITDA was flat YoY at INR749m 13%/3%/11% YoY to INR58.7b/INR4.6b/INR2.4b. animal feed segment in 4QFY19 drove EBIT margin expansion of 250bp QoQ to 5.5%. GOAGRO is planning for two product launches in the standalone crop protection business. In Astec Lifesciences, it has guided for revenue and EBITDA growth of 15% and 20%, respectively, in FY20. We note that 4Q is a seasonally weak quarter for the palm oil business, wherein GOAGRO reported an EBIT loss of INR1m (v/s a profit of INR40m in 4QFY18) due to higher depreciation and interest cost for its new processing plant. (i) GOAGRO will revisit merger initiation with Astec Lifesciences after a few quarters.

Astec Lifesciences Ltd. has lost -17.98% in the last 1 Month

Is Astec Lifesciences Ltd. worth buying?

116 Votes:

Buy 81.03%

Sell 12.07%

Hold 6.9%